Clinical trials: Macular Degeneration
Geographic Atrophy, Age-Related Macular Degeneration
Geographic Atrophy Treatment Evaluation
The purpose of this study was to evaluate the safety and efficacy of AL-8309B Ophthalmic Solution versus Vehicle administered as a topical ocular drop for the treatment for geographic atrophy (GA) secondary to age-related macular…
- Trial name
- GATE (NCT00890097)
- Testing
- AL-8309B Ophthalmic Solution, AL-8309B Vehicle
- Volunteers
- 772 people
- Sponsor
- Alcon Research
Retinal Vein Occlusion
Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO
The study is intended to characterize the clinical benefit regarding safety and efficacy of a long term treatment with Lucentis in comparison with Ozurdex over an additional 6 months and a 3-month follow-up period, following the…
- Trial name
- NCT01580020
- Testing
- RFB002, Dexamethasone
- Where
- 37 sites in Germany
- Volunteers
- 175 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration
Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD
Double-masked, uncontrolled, multi-center, study in which participants will be randomized to one of 3 doses of topical ocular PAN 90806 administered once daily for 12 weeks.
- Trial name
- NCT03479372
- Testing
- PAN-90806 Ophthalmic Suspension
- Where
- 18 sites in United States, Czechia and 3 more
- Volunteers
- 51 people
- Sponsor
- PanOptica, Inc.
Choroidal Neovascularization
Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.
The purpose of this study is to determine whether ranibizumab is effective in the treatment of choroidal neovascularization secondary to causes other then wet macular-degeneration.
- Trial name
- NCT00395551
- Testing
- ranibizumab
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Ophthalmic Consultants of Boston
Periodontitis
Connection Between Periodontitis and Exudative Age-related Macular Degeneration
Aqueous flare is increased in different kind of inflammations of eye. This is caused by disruption of blood-aqueous-barrier. The investigators assume that low grade systemic inflammation, such as periodontitis, increase aqueous…
- Trial name
- FLAREPARO (NCT03958461)
- Testing
- Anti-infective treatment of periodontal pockets
- Where
- Finland
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Helsinki
Neovascular (Wet) Age-Related Macular Degeneration
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment.
- Trial name
- NCT05197270
- Testing
- 4D-150 IVT, Aflibercept IVT
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 215 people
- Sponsor
- 4D Molecular Therapeutics
Age Related Macular Degeneration
MP-1 Biofeedback: Pattern Stimulus Versus Audio-feedback in AMD
Background: Biofeedback techniques have demonstrated their uselfulness in the treatment of maculopathies. We wanted to evaluate the efficacy of visual rehabilitation by means of two different types of biofeedback techniques in…
- Trial name
- NCT01243645
- Testing
- biofeedback training
- Where
- 2 sites in Italy
- Sponsor
- University of Roma La Sapienza
Neovascular Age-Related Macular Degeneration
Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)
The primary objective of the study was to explore the effect of REGN2176-3 on the Early Treatment Diabetic Retinopathy Scale (ETDRS) best-corrected visual acuity (BCVA) in participants with neovascular age-related macular…
- Trial name
- CAPELLA (NCT02418754)
- Testing
- REGN2176-3, Intravitreal Aflibercept Injection (IAI)
- Where
- 84 sites in United States, Japan
- Volunteers
- 505 people
- Sponsor
- Regeneron Pharmaceuticals
Macular Edema
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
This is a study of OZURDEX® use in clinical practice in patients with diabetic macular edema (DME).
- Trial name
- NCT02188173
- Testing
- dexamethasone 700 ㎍ intravitreal implant
- Where
- 18 sites in United States
- Volunteers
- 200 people
- Sponsor
- Allergan
Age Related Macular Degeneration
Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration
Angiogenesis plays a key role in the development of choroidal neovascularizations (CNV) in age-related macular degeneration. Vascular endothelial growth factor (VEGF) is the most important factor involved in this angiogenetic…
- Trial name
- MANTA (NCT00710229)
- Testing
- Ranibizumab, Bevacizumab
- Where
- Austria
- Volunteers
- 320 people
- Sponsor
- The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Macular Edema
Use of Diagnostic Dye to Identify Areas of Leakeage,in the Retina, Prior to Receiving Focal Laser Treatment
The use of Indocyanine green diagnostic dye will identify areas of vascular leakage which will provide more effective laser treatment by targeting these specific areas.
- Trial name
- NCT01792141
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Retina Institute of Hawaii
Age Related Macular Degeneration
Comparison of Treatment rOutine Using afLibERcept: Strict vs relAxed retreatmeNT Regimen
The primary objective of this study is to test non-inferiority of aflibercept "treat and extend" using a relaxed retinal fluid management relative to aflibercept "treat and extend" using a strict retinal fluid management SD-OCT…
- Trial name
- NCT02550002
- Testing
- Aflibercept
- Where
- 2 sites in Switzerland
- Volunteers
- 150 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Retinal Disease, Bestrophinopathy
Stem Cell Models of Best Disease and Other Retinal Degenerative Diseases.
Background: Autosomal recessive bestrophinopathy (ARB) is one of 5 blinding eye diseases caused by mutations in the gene BEST1. These diseases, collectively termed "bestrophinopathies" include ARB, Best vitelliform macular…
- Conditions
- Retinal Disease, Bestrophinopathy, Best Vitelliform Macular Dystrophy, Adult Onset Vitelliform Macular Dystrophy
- Trial name
- NCT02162953
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Mayo Clinic
Diabetic Retinopathy, Macular Degeneration
Intravitreal Infliximab for Diabetic Macular Edema (DME) and Choroidal Neovascularization (CNV)
Injections of medicine into the middle of the eye (intravitreal injections) are commonly used in a multitude of retinal diseases.
- Trial name
- ITVR (NCT00695682)
- Testing
- intravitreal injection of infliximab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Retina Research Foundation
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases
Patients who respond to anti-VEGF therapy but with refractory retinal and choroidal neovascularization diseases including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein…
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT05099094
- Testing
- BD311
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Wet Macular Degeneration
A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration
The present trial will use an open label design to investigate the effect of BI 144807 on central 1-mm retinal thickness and presence of neovascular leakage in newly diagnosed wAMD patients.
- Trial name
- NCT02121522
- Testing
- BI 144807
- Where
- 10 sites in Austria, Germany and 1 more
- Volunteers
- 14 people
- Sponsor
- Boehringer Ingelheim
Uveitis, Vasculitis
The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory Disease
This study will examine the proteins of people with uveitis, or inflammation of the eyes. Evaluating the vitreous, the colorless transparent substance that fills the eyeball in back of the lens, is now possible with the use of…
- Conditions
- Uveitis, Vasculitis, Ocular Inflammatory Disease
- Trial name
- NCT00331331
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- National Eye Institute (NEI)
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Macular Degeneration, Age-related, Geographic Atrophy
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan.
- Trial name
- VERDANT (NCT06722157)
- Testing
- BI 771716, Pegcetacoplan
- Where
- 46 sites in United States
- Volunteers
- 202 people
- Sponsor
- Boehringer Ingelheim
Dry AMD
Morpho-functional Changes After Oral Supplementation of Antioxidants and Anti-inflammatory Treatment in Age-Related Macular Degeneration.
In patients with AMD a deterioration of the antioxidant mechanisms of the retina is observed and therefore an increase in the production of free radicals responsible for tissue damage.
- Trial name
- MACUPREV (NCT03919019)
- Testing
- Macuprev Group
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione G.B. Bietti, IRCCS